1802637-39-3
中文名称
CS-2826
CAS
1802637-39-3
分子式
C26H26ClN5O
分子量
459.97
MOL 文件
1802637-39-3.mol
更新日期
2024/04/29 22:52:17
1802637-39-3 结构式
基本信息
中文别名
(S)-N-(1-(1H-苯并[D]咪唑-2-基)-4-(2-氯乙酰亚胺基)丁基)-[1,1'-联苯基]-4-甲酰胺 英文别名
CS-2826BB-Cl-Amidine
N-{(1S)-1-(1H-Benzimidazol-2-yl)-4-[(2-chloroethanimidoyl)amino]butyl}-4-biphenylcarboxamide
[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-
常见问题列表
生物活性
BB-Cl-Amidine 是肽基精氨酸脱胺酶 (PAD) 的抑制剂。靶点
PAD.
体内研究
Treatment with BB-Cl-amidine subtly reduces splenomegaly in MRL/lpr mice, while there is a trend towards increased circulating levels of anti-NET antibodies with PAD inhibitor treatment. However, neither PAD inhibitor affected body weight or total IgG levels. Indeed, treatment with both Cl-amidine and BB-Cl-amidine significantly improves endothelium-dependent vasorelaxation. The BB-Cl-amidine group also shows a strong trend towards downregulation of IRGs. Treatment with either Cl-amidine or BB-Cl-amidine significantly improves muzzle alopecia, in many cases preventing it entirely.
| Animal Model: | MRL/lpr mice. |
| Dosage: | 1 mg/kg. |
| Administration: | Subcutaneous injection daily from 8 to 14 weeks of age. |
| Result: | Significantly improved endothelium-dependent vasorelaxation and showed a strong trend towards downregulation of IRGs. |